Actavis confirms court ruling in generic patent suit

DUBLIN — Actavis confirmed that the U.S. District Court for the District of Delaware found certain claims of U.S. Patent Nos. 6,335,031 and 6,316,023 valid and infringed by the company's rivastigmine transdermal system, a generic version of Exelon Patch from Novartis.



Actavis said it is reviewing the court's decision and weighing all available options, including an appeal.



Exelon Patch is used to treat patients with mild to moderate dementia associated with Alzheimer's or Parkinson's disease. Actavis' abbreviated new drug application for its generic version of Exelon Patch is pending with the Food and Drug Administration.